Concurrent Assessment of Skeletal Muscle Mass and Synthesis/Breakdown in Old Age

University of Nottingham37 enrolled

Overview

This study involves minimally-invasive techniques to measure muscle mass, muscle protein breakdown and synthesis simultaneously in older age.

Most people will have noticed that with age people become frail. This is principally due to wasting of skeletal muscle known as "sarcopenia". Crucially, sarcopenia is more than just a symptom of weakness and poor functional capacity; it exposes people to an increased risk of falls and fractures, impacting quality of life, independence, health status and ultimately lifespan. Muscles represent the largest organ in the body, making up over 50% of total body weight. Most people know that skeletal muscles are important for movement and to support the skeleton, but not everyone is aware of how important muscles are for whole-body health. For example, muscles represent a vast protein store containing amino acids (the building blocks of protein) which can be broken down in times of fasting, infection and disease in order to provide energy to help other vital organs. Because of the detrimental effects on health, and the associated health costs, sarcopenia is of grave concern. Therefore, there is a significant clinical need to pre-identify at-risk older individuals who have low muscle mass so that they can be offered an intervention (of diet, exercise or drug-based) before they suffer any of the potential problems outlined above. Current techniques for measuring whole-body muscle mass, including MRI and CT are time-consuming, expensive and in huge demand in hospital settings, meaning that muscle wasting conditions such as sarcopenia often go undiagnosed. In this project we propose a potential solution to this problem by developing a diagnostic of sarcopenia that requires only a single drink and subsequent urine collection. In addition, throughout this project we aim to explore the mechanisms underlying muscle wasting by assessing the muscle of those with low and 'normal' muscle mass.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Sarcopenia Muscle Atrophy

Interventions

D3-CreatineOTHER

30mg D3-Creatine to measure muscle mass

Deuterium OxideOTHER

D2O provided to measure muscle protein synthesis

D3-3-methylhistidineOTHER

D3-3-methylhistidine is provided to measure muscle protein breakdown

Eligibility

Sex: ALLMin age: 65 YearsMax age: 85 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: \- Healthy volunteers of normal body mass index (BMI \<35 kg/m2), aged 65-85 years Exclusion Criteria: * A BMI \> 35 kg/m2 * Active cardiovascular disease: o angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt, recent cardiac event * Cerebrovascular disease: o previous stroke, aneurysm (large vessel or intracranial), epilepsy * Respiratory disease including: o pulmonary hypertension, COPD * Metabolic disease: o hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, type 1 or 2 diabetes * Active inflammatory bowel or renal disease * Malignancy * Recent steroid treatment (within 6 months) or hormone replacement therapy * Clotting dysfunction

Locations (1)

Royal Derby Hospital Medical School

Derby, Derbyshire, United Kingdom

Outcomes

Primary Outcomes

Measurement of D3-Creatine in Urine: 24 hours

Time frame: Up to 24 hours

Measurement of muscle mass using D3-Creatine: 48 hours

To use 30mg of D3-Creatine to measure muscle creatine pool size (g) and whole-body muscle mass (kg) from urine samples taken between 0 and 72 hours. The 0-24 hours collection provides a measure of creatine spillover, spot urines at 48 and 72 hours provide a measurement of the dilution of tracer in urinary creatinine and thus the total muscle creatine pool size.

Time frame: 48 hours

Measurement of muscle mass using D3-Creatine: 72 hours

Time frame: 72 hours

Rate of dilution of D3-3MH by endogenous unlabelled 3MH release in blood

Using 10mg of D3-3-methylhistidine (D3-3MH) and subsequent multiple blood sampling between 24 and 30h, the rate of dilution of D3-3MH by endogenous unlabelled 3MH release provides a measure of the rate of whole-body muscle protein breakdown.

Time frame: 6 hours (from 24 through to 30 hours)

Rates of Muscle Protein Synthesis

Using D2O, rate of muscle protein synthesis will be calculated, cumulatively, over 0-3 days by measuring deuterium labelling of alanine into protein from a muscle biopsy at 72 hours.

Time frame: 3 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.